Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Voyager Therapeut (VYGR)

Voyager Therapeut (VYGR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 634,895
  • Shares Outstanding, K 36,934
  • Annual Sales, $ 7,620 K
  • Annual Income, $ -88,290 K
  • 60-Month Beta 2.63
  • Price/Sales 82.26
  • Price/Cash Flow N/A
  • Price/Book 5.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.87
  • Number of Estimates 6
  • High Estimate -0.69
  • Low Estimate -1.04
  • Prior Year -0.63
  • Growth Rate Est. (year over year) -38.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.81 +8.73%
on 09/09/19
22.13 -22.32%
on 08/20/19
-3.37 (-16.39%)
since 08/13/19
3-Month
15.81 +8.73%
on 09/09/19
28.79 -40.29%
on 06/20/19
-7.49 (-30.35%)
since 06/13/19
52-Week
7.76 +121.52%
on 01/24/19
28.79 -40.29%
on 06/20/19
-2.36 (-12.07%)
since 09/13/18

Most Recent Stories

More News
Voyager Therapeutics to Present at Upcoming Investor Conferences in September 2019

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced management presentations...

WFC : 48.92 (+0.55%)
VYGR : 17.19 (+1.30%)
Voyager Therapeutics (VYGR) Q2 Earnings and Revenues Top Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 132.95% and 777.85%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

VYGR : 17.19 (+1.30%)
Voyager Therapeutics: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Voyager Therapeutics Inc. (VYGR) on Friday reported second-quarter net income of $11.2 million, after reporting a loss in the same period a year earlier.

VYGR : 17.19 (+1.30%)
Voyager Therapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights

Gained worldwide rights to VY-HTT01 for Huntington's disease, expanding wholly-owned pipeline

VYGR : 17.19 (+1.30%)
Voyager Therapeutics to Host Second Quarter 2019 Financial Results and Corporate Highlights Conference Call

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced that it will report its...

VYGR : 17.19 (+1.30%)
Voyager Therapeutics to Present at Upcoming Investor Conferences in August 2019

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced management presentations...

VYGR : 17.19 (+1.30%)
Voyager Therapeutics Announces Management Updates

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the retirement of Dinah...

VYGR : 17.19 (+1.30%)
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -2.53% and 73.06%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

VYGR : 17.19 (+1.30%)
Voyager Therapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights

FDA grants orphan-drug designation for VY-HTT01 for Huntington's disease

VYGR : 17.19 (+1.30%)
Voyager Therapeutics: 1Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Voyager Therapeutics Inc. (VYGR) on Tuesday reported a loss of $27.2 million in its first quarter.

VYGR : 17.19 (+1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade VYGR with:

Business Summary

Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs...

See More

Key Turning Points

2nd Resistance Point 17.71
1st Resistance Point 17.45
Last Price 17.19
1st Support Level 16.87
2nd Support Level 16.55

See More

52-Week High 28.79
Fibonacci 61.8% 20.76
Fibonacci 50% 18.28
Last Price 17.19
Fibonacci 38.2% 15.79
52-Week Low 7.76

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar